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ORIGINAL INVESTIGATION
Prevalence of left ventricular systolic 
dysfunction and heart failure with reduced 
ejection fraction in men and women with type 
2 diabetes mellitus: a systematic review 
and meta-analysis
Selma Bouthoorn1†, Aisha Gohar1,2*† , Gideon Valstar1,2, Hester M. den Ruijter2, J. B. Reitsma1, Arno W. Hoes1 
and Frans H. Rutten1 on behalf of the Queen of Hearts Consortium
Abstract 
Background: Type 2 diabetes mellitus (T2D) is associated with the development of left ventricular systolic dys-
function (LVSD) and heart failure with reduced ejection fraction (HFrEF). T2D patients with LVSD are at higher risk of 
mortality and morbidity than patients without LVSD, while progression of LVSD can be delayed or halted by the use of 
proven therapies. As estimates of the prevalence are scarce and vary considerably, the aim of this study was to retrieve 
summary estimates of the prevalence of LVSD/HFrEF in T2D and to see if there were any sex differences.
Methods: A systematic search of Medline and Embase was performed to extract the prevalence of LVSD/HFrEF in 
T2D (17 studies, mean age 50.1 ± 6.3 to 71.5 ± 7.5), which were pooled using random-effects meta-analysis.
Results: The pooled prevalence of LVSD was higher in hospital populations (13 studies, n = 5835, 18% [95% CI 
17–19%]), than in the general population (4 studies, n = 1707, 2% [95% CI 2–3%]). Seven studies in total reported sex-
stratified prevalence estimates (men: 7% [95% CI 5–8%] vs. women: 1.3% [95% CI 0.0.2.2%]). The prevalence of HFrEF 
was available in one general population study (5.8% [95% CI 3.7.6%], men: 6.8% vs. women: 3.0%).
Conclusions: The summary prevalence of LVSD is higher among T2D patients from a hospital setting compared 
with from the general population, with a higher prevalence in men than in women in both settings. The prevalence 
of HFrEF among T2D in the population was only assessed in a single study and again was higher among men than 
women.
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Introduction
Type 2 diabetes mellitus (T2D) is a major risk factor for 
all types of heart failure (HF) and causes an increase in 
mortality and morbidity in patients with HF [1]. Under 
recognition of HF in T2D is an important problem with 
prevalence rates of unrecognized HF being reported as 
high as around 25% in the community aged 60 years and 
over [2]. T2D is commonly seen with coronary artery 
disease (CAD) [3]. Ischaemic heart disease is the usual 
cause of the left ventricular systolic dysfunction (LVSD) 
seen in HF with reduced ejection fraction (HFrEF). This 
subtype of HF is commonly reported as accounting for 
approximately 50% of all cases of HF, but this proportion 
may be lower in the general population/screen-detected 
HF [4] than in large HF cohorts including post-discharge/
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outpatient cohorts [5]. The number of people with T2D 
continues to rise worldwide having a profound impact 
upon society in terms of health burden and healthcare 
expenditure [6]. On the other hand, HFrEF is declining 
in prevalence, likely due to improved preventative and 
early treatment strategies, such as early revascularisa-
tion, which have led to a fall in the occurrence of ischae-
mic heart disease, notably acute ST-elevation myocardial 
infarction [7]. Despite this, the risk of all-cause mortal-
ity and cardiac hospitalization remains high and some 
studies report higher rates in HFrEF patients than in 
patients with heart failure with preserved ejection frac-
tion (HFpEF) [8]. LVSD, the pre-clinical phase of HFrEF, 
is also associated with a poor outcome [9]. Unlike HFpEF, 
there is proven treatment for patients with LVSD that 
can delay or even prevent the progression of asympto-
matic LVSD to symptomatic HF i.e. HFrEF [10]. There-
fore identifying LVSD at an early pre-clinical stage is 
extremely useful in improving survival in T2D patients. 
Given the high prevalence of (unrecognized) HFrEF in 
T2D patients, the poor prognosis and available effective 
therapies, the implementation of screening-programmes 
in T2D patients with natriuretic peptides has been sug-
gested to identify LV dysfunction in its pre-clinical phase 
[11]. However it is first imperative to know the exact 
prevalence rates of LVSD in T2D patients prior to imple-
menting such approaches. Previous studies regarding 
prevalence rates of LVSD in T2D did not look at HFrEF 
and HFpEF separately, and also only looked at T2D 
patients in secondary care and not from the general pop-
ulation. Therefore we performed an extensive systematic 
review and meta-analysis, reviewing existing literature 
to estimate the prevalence of LVSD and HFrEF in T2D 
patients both in a hospital setting and a general popula-
tion setting. Given the difference in prevalence rates of 
HF between men and women, and the higher prevalence 
of T2D in men, we were also interested to see if the prev-
alence rates differed by sex.
Methods
Literature search
A literature search was initially performed using the 
Medline and Embase databases including all studies up to 
and including May 2016. The search terms and synonyms 
used were ‘heart failure’, ‘systolic ventricular dysfunction’, 
‘diabetes mellitus, type 2’, ‘prevalence’ and ‘incidence’. The 
search was repeated in March 2018 including all studies 
previously included and studies performed since the last 
literature search. For the exact search strategy see Addi-
tional file 1: Table S1. Of the studies retrieved for full text 
assessment, reference lists were screened for other rel-
evant studies.
Selection of articles
The following predefined inclusion criteria were applied: 
(i) The study reported the prevalence of HFrEF and/or 
LVSD in patients with T2D. (ii) The study population was 
derived from the population at large or from the hospi-
tal population. (iii) Only studies were included that used 
echocardiography to establish or confirm the diagnosis 
of HFrEF and/or LVSD. (iv) T2D defined by one of the 
following criteria: documentation in the medical record, 
physicians diagnosis, self-reported history, use of anti-
diabetic agents and random serum glucose ≥ 200 mg/dL 
(or ≥ 11.1 mmol/L) or serum fasting glucose ≥ 126 mg/
dL (or ≥ 7.0 mmol/L).
Only studies published in the English language were 
considered. Letters, editorials, case reports, practical 
guidelines and animal or in vitro studies were excluded.
If multiple studies were based on the same study pop-
ulation, the study with the largest population for data 
extraction was selected. Selection of publications and 
data extraction was done independently by three review-
ers (SB, GV and AG). Consensus was used to resolve dis-
agreement. If consensus could not be reached, a fourth 
reviewer (FR) was consulted.
Quality assessment
A methodological quality assessment of each of the 
included studies was performed independently by three 
authors (SB, GV and AG). In case of discrepancies, con-
sensus was reached after discussion. As there is no for-
mal checklist available specifically designed to appraise 
risk of bias in prevalence studies, we based our assess-
ment on the risk of bias tool of Hoy et al. [12]. This is a 
new risk of bias tool for prevalence studies based on a 
modification of an existing tool and on the approach of 
the QUADAS-2 (tool for the quality assessment of diag-
nostic accuracy studies) [13]. Signalling questions were 
used to identify potential problems in the design, con-
duct and analysis of a study that might introduce bias or 
raise concerns about the applicability of the findings. The 
following signalling questions were used:
(a) Has the correct population/setting been targeted 
in order to answer the research question (T2D 
patients in the general population, referral centres, 
hospital centre)?
(b) Is the sampling frame a true or close representation 
of this target population intended by the research 
question?
(c) Is an unselected (random/consecutive) sample of 
patients invited to participate?
(d) Is the response rate ≥ 75% or did a non-response 
analysis show no difference between participants 
and nonparticipants?
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(e) Is an acceptable case definition for LVSD and/or 
HFrEF used in the study?
(f ) Is the instrument to measure LVSD and/or HFrEF 
valid?
(g) Is the same mode of data collection used for all sub-
jects?
(h) Is it unlikely that the handling of missing (endpoint) 
data introduced bias?
(i)  Were the numerator(s) and denominator(s) for the 
parameter of interest appropriate?
All signalling questions were scored with either low 
or high risk of bias. Overall risk of bias was classified as 
low (if ≤ 1 question was answered high), medium (if 2–3 
questions were answered high) or high (if > 3 questions 
were answered high).
Data extraction and analysis
Information on study characteristics was collected with 
a data extraction form and comprised of first author’s 
name, publication year, source population and setting, 
age, number of participants, duration of T2D, exclusion 
criteria, echocardiographic measurements used, left 
ventricular ejection fraction (LVEF) threshold used and 
prevalence estimates of HFrEF and/or LVSD. Prevalence 
numerators and denominators were extracted from the 
studies. Individual study prevalence and corresponding 
95% confidence intervals (95% CI) were calculated for all 
the included studies. To perform the meta-analysis, the 
prevalence data were log transformed so that the data 
followed a normal distribution. Given the inclusion of 
some studies with a zero prevalence of LVSD or HFrEF, 
the Freeman–Tukey transformation was performed [14]. 
A random-effects model was used to obtain pooled esti-
mates (with corresponding 95% CI) of the transformed 
prevalence data. This model takes into account the 
between-study heterogeneity. Heterogeneity was assessed 
using the Cochrane Q test and the  I2 statistic [15]. The 
pooled prevalence estimate was calculated for all of the 
included studies, and separately for studies concerning 
the general population and hospital population. Sex-spe-
cific pooled estimates were calculated for both sexes with 
the two settings combined. Results of the meta-analysis 
are presented as Forest plots showing prevalence pro-
portions with corresponding 95% CIs for each study and 
the overall random-effects pooled estimate. Publication 
bias was first assessed by visually inspecting the distribu-
tion of observed studies on a funnel plot (Additional files 
2: Figure  S1 and Additional file  3: Figure  S2). To quan-
tify the degree of bias illustrated in the funnel plot, the 
Begg’s rank correlation test and Egger’s linear regression 
were used [16, 17]. A p < 0.05 was considered statistically 
significant. All statistical analyses were performed in R by 
using the ‘metafor’ package [18].
Results
Search results and characteristics
In total the search resulted in 6882 potentially relevant 
studies. These studies were first screened on title and 
then on abstract for eligibility. Full text articles were addi-
tionally screened of 292 studies for more detailed infor-
mation. The main reasons for exclusion included the lack 
of T2D in the population, no information regarding HF 
or LVSD/HFrEF and lack of echocardiographic data. Thus 
17 studies were eventually included in this review. Details 
of the selection process are provided in Fig.  1. Study 
characteristics and quality assessment of all the included 
studies are shown in Table 1. Of the 17 included studies, 
13 included participants derived from a hospital setting 
[3, 19–30]. The majority of these hospital setting stud-
ies were in the outpatient setting with only one including 
hospitalized patients. Four studies consisted of patients 
from the general population [2, 31–33]. All studies con-
sisted of data regarding the prevalence of LVSD with only 
one study containing data on the prevalence of HFrEF in 
addition to LVSD (Table 1) [2]. The mean age in the stud-
ies ranged from 50.1 ± 6.3 to 71.5 ± 7.5. The LVEF cut-off 
point ranged from 45–55% with the majority of studies 
using 50% (n = 12). Most studies had a medium risk of 
bias (n = 12). 
Prevalence of LVSD and HFrEF
The pooled prevalence estimate for all 17 included studies 
(both hospital setting and general population setting) was 
13% [95% CI 13–14%] (Fig. 2). For the 13 studies in the 
hospital population and the 4 studies in the general pop-
ulation the pooled estimates were 18% [95% CI 17–19%] 
and 2% [95% CI 2–3%] respectively (Figs. 3 and 4). Esti-
mates ranged from 0 to 52% in the hospital setting and 
1 to 7% in the general population setting. Heterogeneity 
was higher for the hospital setting (Q = 593.3, p < 0.001, 
 I2 = 98.5% than the general population setting (Q = 24.8, 
p < 0.001,  I2 = %). There was no potential risk of publica-
tion bias Begg’s (p = 0.95 and p = 0.33 respectively) and 
Egger’s test (p = 0.31 and p = 0.06 respectively).  
Sex-stratified prevalence rates were only available for 
seven studies (both hospital setting and general setting 
combined). In three of these studies the total prevalence 
of LVSD was 0%; thus the overall prevalence in the seven 
studies reporting sex-specific findings was consider-
ably lower than in the 17 studies combined. Sex-specific 
pooled estimates in these seven studies were 7% [95% CI 
5–8%] for men and 0.1% [95% CI 0.6–2%] in women. The 
sex-specific pooled estimates from the hospital setting 
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Potentially relevant articles identified and screened for retrieval (n=6882)
6590 articles excluded based on title and abstract 
Potentially relevant articles identified and screened (n=292)
Articles selected (n= 16) 
276 articles excluded based on full text
Reasons for exclusion:
Missing information on T2D, heart failure 
or systolic dysfunction: 94
No echocardiographic measurements: 95
No prevalence data reported: 18
Other domain: 34
Identical study population: 16
No full text available: 11
Conference paper: 2
Not in English language: 1
Wrong design: 5
1 cross-reference
Articles included for review (n= 17) 
Fig. 1 Flow chart of the process for selection of relevant articles
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were: 9% [95% CI 7–10%] in men vs. 2% [95% CI 1–4%] 
in women. Only one study looked at sex-specific preva-
lence estimates from the general population (1.3% [95% 
CI 0–3%] in men vs. 0.0% [95% CI 0–0.1%] in women).
The prevalence of HFrEF was only available in one 
study, performed by Boonman et  al. using a sam-
ple from the general population of T2D patients aged 
60  years or over. As this study screened for previously 
unknown HFrEF in addition to LVSD, individuals with 
an established diagnosis of HF were excluded from the 
main analyses from their study. The estimates of LVSD of 
participants without previously known HF at the start of 
the study can be viewed in the forest plots (Figs.  2 and 
4) and stratified by sex in Fig. 5. In this study, Boonman 
et  al. reported the prevalence of HFrEF, based on an 
LVEF < 45% and including individuals known to have HF 
at the start of the study to be 5.8% [95% CI 3.9–7.6%]. The 
corresponding prevalence of HFrEF in men and women 
Fig. 2 Prevalence of left ventricular systolic dysfunction among 7542 T2D patients in both the general and hospital population. *Study by Boon-
man et al. is a HF-screening study which was performed in the general population. The corresponding estimate of LVSD is made up from a sample 
excluding individuals with previously known HF at the start of the study
Fig. 3 Prevalence of left ventricular systolic dysfunction among 5835 T2D patients in the hospital setting
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without previously known HF was higher in men than 
women (6.8% vs. 3.0%).
Discussion
Our systematic review and meta-analysis showed that the 
prevalence of LVSD is on average higher when specifi-
cally looking at studies enrolling patients from a hospital 
setting (18% [95% CI 17–19%] than those from the gen-
eral population (2% [95% CI 2–3%]. The latter includes 
the correct denominator when assessing the prevalence 
in T2D, and as such provides the more accurate preva-
lence estimate [34]. In only six hospital studies with in 
total 1205 men and 761 women, sex-specific estimates 
were reported; the prevalence of LVSD among men with 
T2D was 9% [95% CI 7–10%] and in women 2% [95% 
CI 1–4%]. In the only study from the general popula-
tion reporting sex-specific estimates the prevalence of 
LVSD in men was 1.3% [95% CI 0–3%] and in women 
0% [95% CI 0–0.1%]. There was large heterogeneity in 
the published prevalences and the population making 
up the hospital setting was more heterogeneous than 
the population included in the general population stud-
ies. It is important to note that heterogeneity is generally 
higher in diagnostic/prevalence studies than drug tri-
als as these studies consist of ‘real life’ people from the 
population with a multitude of comorbidities and of an 
older age. This is in contrast to participants in drug trials 
who are subject to strict inclusion and exclusion criteria 
and therefore are generally younger and usually have only 
one disease, which leads to lower heterogeneity. The rea-
sons for the heterogeneity we see in our review include 
the selection criteria used. Although, T2D patients in 
the hospital setting are more diseased and have more 
comorbidities than those from the general population, 
in the studies providing estimates, 10 out of the 13 hos-
pital population studies excluded patients with a his-
tory of cardiovascular disease [19, 20, 22, 23, 25, 27, 33] 
or other diseases, such as hypertension [19, 24, 26, 30], 
atrial fibrillation [20, 25, 33] and renal impairment [23, 
27], that are (potentially) in the causal pathway in the 
development of LVSD/HFrEF. This will have resulted in 
an underestimation of the prevalence. One reason for 
exclusion of these diseases provided by the authors of 
such publications was the independent impact these dis-
eases have on LV function [27]. This, however, is some-
what counterintuitive as HFrEF does not merely develop 
‘out of the blue’, that is, in patients without any CV his-
tory, known or unknown. Another reason for the possible 
heterogeneity in the hospital population studies could be 
the duration of T2D. This was not reported in 4 out of the 
13 studies. However there does not appear to be a rela-
tionship between the duration of T2D and the prevalence 
of LVSD. Age may explain some of the heterogeneity pre-
sent as the studies with the oldest participants (Chaow-
alit et al. and Faden et al.) also had the highest reported 
prevalence of LVSD. The study with the youngest partici-
pants (Chaudhary et al.) had a LVSD prevalence of 0%.
There were only four studies performed in a sam-
ple from the general population. Three of these stud-
ies (Srivastava et  al., Dandamundi et  al. and Xanthakis 
et  al.) showed similar estimates, using LVEF 50% as a 
cut point and only providing data on LVSD. The fourth 
study, by Boonman et al. used LVEF 45% as a cut point 
and it was the only study providing data on HFrEF in 
Fig. 4 Prevalence of left ventricular systolic dysfunction among 1707 T2D patients in the general population setting. *Study by Boonman et al. is 
a HF-screening study which was performed in the general population. The corresponding estimate of LVSD is made up from a sample excluding 
individuals with previously known HF at the start of the study
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addition to LVSD. This study presented an estimate of 
1% for LVSD, while for HFrEF it was 5.8%. It is impor-
tant to note that this study was a HF-screening study 
with the aim of identifying previously unrecognized HF 
in the community. Therefore participants with previ-
ously known HF were removed from the study and from 
analyses involving LVSD. The authors did provide data on 
the estimate of HFrEF including participants previously 
known to have HF. Given the nature of the study, partici-
pants with a LVEF < 45% were scrutinized for the slight-
est suggestion of symptoms, such as shortness of breath 
(MRC 2 was considered to be dyspnoea) and were subse-
quently labelled as HFrEF instead of LVSD. It is only the 
symptoms, (and possibly signs) of HF that may be con-
sidered to be the difference between LVSD and HFrEF, 
which is a clinician-based observation. This may explain 
the somewhat lower estimate of LVSD seen between this 
study (1%) compared to the other general population 
studies by Srivastava et al. (5%), Dandamundi et al. (7%) 
and Xanthakis et al. (3%) which did not assess HF symp-
toms and thus included “symptomatic” LVSD (i.e. HFrEF) 
as the numerator.
CAD can be silent in patients with T2D, more so than 
in those without T2D. Therefore it could be more dif-
ficult to pick up HF in these patients in the pre-clinical 
phase. In addition, due to the non-specific nature of the 
Fig. 5 Prevalence of left ventricular systolic dysfunction among a 1515 male T2D patients and b 1032 female T2D patients in both the general and 
hospital population. *Study by Boonman et al. is a HF-screening study which was performed in the general population. The corresponding estimate 
of LVSD is made up from a sample excluding individuals with previously known HF at the start of the study
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disease, HF can be difficult to diagnose prior to echocar-
diography, therefore remaining unrecognized in the com-
munity, leaving patients untreated. We report an overall 
higher prevalence of LVSD in the T2D population com-
pared with the prevalence of LVSD in the general popu-
lation [35]. Given that there is proven therapy available 
for LVSD/HFrEF [10], our results highlight the impor-
tance of timely detection of HF in men and women with 
T2D. Screening by way of measuring NTproBNP levels to 
identify patients early is a possible option so that man-
agement can be provided in a timely manner. Patients 
with both HFrEF and T2D have been found to have high 
mortality rates, with up to a tenfold increase in mortal-
ity [1]. This has been explained by the association of T2D 
with features of adverse structural and functional cardiac 
remodelling in patients with HF [36]. This high mortal-
ity, in addition with the rapidly rising prevalence of T2D 
globally due to obesity and lack of exercise [6], only 
strengthens the argument for screening of HF in these 
patients. New, more sensitive echocardiographic tech-
niques have enabled the non-invasive detection of LVSD 
underlying HF in diabetes at an early stage [37] making 
it easier to diagnose LVSD and HF in a high risk popula-
tion, such as T2D as we see here. The cost-effectiveness 
of screening for HF in diabetic patients has also already 
been proven [38] further highlighting the usefulness of 
screening high-risk patient groups, such as T2D for HF.
Men are known to be at a higher risk of developing 
LVSD/HFrEF than women. This is likely due to the higher 
prevalence of coronary macrovascular disease seen in 
men than women. Of the seven studies with sex-stratified 
data, only the study by Boonman et al. was performed in 
the general population. The overall prevalence of HFrEF 
was indeed higher in men than in women.
There are a number of limitations of our review. As 
mentioned, there was significant heterogeneity between 
the hospital-based studies. This, however is a known fea-
ture of meta-analyses regarding prevalence rates [39]. In 
addition to the exclusion criteria used, this can also be 
explained, albeit to a lesser extent, by the differences in 
cut-off LVEFs used for each study with cut-offs ranging 
from 45 to 55%, the applied cut points for other echo-
cardiographic parameters, and also by differences in age, 
year of study and sample size. Low numbers of included 
studies set in the general population is also a limitation 
of this review as we were unable to adequately compare 
the pooled prevalence of these patients with the pooled 
prevalence of the patients included within the hospital 
setting. The same also holds true when comparing the 
pooled prevalence rates between men and women.
Conclusion
In conclusion, from 17 studies including a low number 
of patients in total, the summary prevalence of LVSD 
among T2D patients in a hospital setting is much higher 
(around 18%) than in samples from the general popula-
tion (around 2%). The prevalence is higher in men as 
compared to women in both settings. The prevalence of 
HFrEF, only assessed in one study, was also higher among 
men than women.
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